Page last updated: 2024-11-02

pioglitazone and Inflammatory Bowel Diseases

pioglitazone has been researched along with Inflammatory Bowel Diseases in 3 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.

Research Excerpts

ExcerptRelevanceReference
" Moreover, macrophage PPAR-γ was required for accelerating pioglitazone-mediated recovery from dextran sodium sulfate (DSS) colitis, providing a cellular target for the anti-inflammatory effects of PPAR-γ agonists in IBD."3.77Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. ( Bassaganya-Riera, J; Climent, M; Evans, C; Guri, AJ; Hontecillas, R; Horne, WT; Sobral, BW; Zhang, Y, 2011)
" The present study aimed to investigate the effect of different doses of pioglitazone alone and in combination with sulfasalazine in TNBS (trinitrobenzenesulfonic acid)-induced inflammatory bowel disease (IBD) in rats."1.39Comparative evaluation of different doses of PPAR-γ agonist alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats. ( Byrav D S, P; Chakrabarti, A; Khanduja, KL; Medhi, B; Prakash, A; Vaiphei, K, 2013)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
da Rocha, GHO1
Loiola, RA1
de Paula-Silva, M1
Shimizu, F1
Kanda, T1
Vieira, A1
Gosselet, F1
Farsky, SHP1
Byrav D S, P1
Medhi, B1
Prakash, A1
Chakrabarti, A1
Vaiphei, K1
Khanduja, KL1
Hontecillas, R1
Horne, WT1
Climent, M1
Guri, AJ1
Evans, C1
Zhang, Y1
Sobral, BW1
Bassaganya-Riera, J1

Other Studies

3 other studies available for pioglitazone and Inflammatory Bowel Diseases

ArticleYear
Pioglitazone Attenuates the Effects of Peripheral Inflammation in a Human In Vitro Blood-Brain Barrier Model.
    International journal of molecular sciences, 2022, Oct-24, Volume: 23, Issue:21

    Topics: Blood-Brain Barrier; Claudin-5; Humans; Inflammation; Inflammatory Bowel Diseases; Intercellular Adh

2022
Comparative evaluation of different doses of PPAR-γ agonist alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats.
    Pharmacological reports : PR, 2013, Volume: 65, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Therapy, Co

2013
Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.
    Mucosal immunology, 2011, Volume: 4, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Colitis; Colon; Computational Biology; Dextran S

2011